Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer - PubMed
6 hours ago
- #androgen receptor inhibitors
- #Ki-67 proliferation
- #prostate cancer
- Higher proliferation (Ki-67 index) in prostate cancer tumors is strongly prognostic for shorter overall survival.
- In metastatic prostate cancer patients, adding abiraterone to androgen deprivation therapy (ADT) attenuates the adverse effect of high Ki-67.
- A statistically significant interaction shows that highly proliferative metastatic tumors derive greater benefit from intensified androgen receptor pathway inhibition.
- No similar treatment-biomarker interaction was observed in non-metastatic prostate cancer.
- Ki-67 is an independent prognostic biomarker in advanced prostate cancer and suggests a biological vulnerability of rapidly cycling tumors to AR pathway blockade.